Celldex Therapeutics Inc. (NASDAQ: CLDX) completed an underwritten public offering of 11,896,750 shares of common stock at $29.00 per share, the company announced. The offering included the full exercise of underwriters' option to purchase an additional 1,551,750 shares.

The biotechnology company received gross proceeds of approximately $345 million from the offering, before deducting underwriting discounts, commissions and other expenses. All shares in the offering were sold by Celldex.

Leerink Partners, TD Cowen, Guggenheim Securities and Cantor served as joint bookrunning managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-lead managers.

The shares were offered under a shelf registration statement on Form S-3 that became automatically effective on November 3, 2023. The offering was conducted through a prospectus supplement and accompanying prospectus filed with the Securities and Exchange Commission.

Celldex is a clinical-stage biotechnology company developing antibody-based therapeutics for inflammatory, allergic, autoimmune and other diseases. The company focuses on mast cell biology and treatments that engage the immune system or affect critical pathways.